- Healthcare 150
- Posts
- +54% in 3 Years: The Rise of the Self-Pay Patient
+54% in 3 Years: The Rise of the Self-Pay Patient
Today we’re unpacking the rise of the self-pay patient and the strain on healthcare collections.
Good morning, ! Today we’re unpacking the rise of the self-pay patient and the strain on healthcare collections, Infosys’ $560M push into vertical healthcare and insurance capabilities, and Japan’s accelerating shift toward global pharma M&A.
Want to advertise in Healthcare 150? Check out our ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
MICROSURVEY
How have your organization’s operating margins changed over the past 12 months? |
HEADLINE OF THE WEEK
The Patient Becomes the Payor (and the Problem)
Nearly 40% of healthcare collections now come from uninsured patients, up 54% in three years—turning providers into reluctant lenders. The shift isn’t subtle: rising out-of-pocket costs, fueled by high-deductible plans, are outpacing wages and inflation. Result? Patients are behaving less like consumers and more like distressed borrowers.
The data is blunt: 30% say payment options are unaffordable, and 1 in 4 struggle to pay bills. Meanwhile, legacy collections models—built on stale data—are missing the moment, especially for “at-risk patients” who delay payments and report significantly lower satisfaction.
The twist: patients are increasingly turning to AI tools to decode bills—effectively outsourcing clarity where the system hasn’t delivered.
Bottom line: Healthcare’s revenue cycle is being stress-tested—and technology may be the only scalable fix. (More)
PRESENTED BY JUNIPER SQUARE
Stop adding more tools or service providers. Get the best of both with a fund operations partner.
The LP experience can make or break fundraising because investors remember how it feels to work with your firm: onboarding, responsiveness, reporting, and the confidence they have in the numbers.
That experience is only as strong as the operating model behind it. When fund and investor data live across disconnected systems, delays and inconsistencies show up fast.
Juniper Square is the fund operations partner for PE GPs, combining software + fund administration services built on a common data foundation. That means fewer failure points, clearer visibility across investor workflows, and a modern investor experience powered by a single source of truth.
Book a demo to see how a fund operations partner
DEAL OF THE WEEK
Infosys Deploys $560M to Buy Healthcare and Insurance Depth
Infosys is acquiring Optimum Healthcare IT for up to $465M and Stratus Global for $95M, bringing total deal value to $560M and pushing its FY26 M&A spend to $808M, the highest in over two decades.
This is not scale for scale’s sake. Optimum adds provider-side implementation depth in EHR and digital transformation, while Stratus strengthens Guidewire and P&C insurance capabilities. Together, they move Infosys further away from horizontal IT services toward verticalized, domain-led delivery.
The financial signal is material. The deals add roughly $319M in incremental revenue and are expected to drive 2–2.5% inorganic growth in FY27. Nearly half of recent growth is now acquisition-driven, a notable shift for a firm historically reliant on organic expansion.
The strategic layer is clearer. Infosys is pairing domain expertise with its Topaz AI and Cobalt cloud stack, effectively betting that AI alone will not differentiate vendors without embedded workflow and regulatory knowledge.
Why it matters now: Healthcare and insurance buyers are moving past generic AI pilots toward execution partners with domain credibility. This deal positions Infosys to compete for higher-margin, transformation-led contracts, but raises integration risk as inorganic growth becomes a larger share of the story. (More)
REGIONAL FOCUS
Japan Goes Global in Pharma M&A
Japan’s pharma sector is undergoing a quiet but decisive shift, from domestic R&D-led growth to global dealmaking.
The chart tells the story. After years of muted activity, deal count surged to 33 in 2024, with sustained momentum into 2025, while capital deployment remains volatile with periodic spikes (e.g., $349.7M in 2019). This signals a market transitioning from opportunistic to strategic, pipeline-driven acquisitions.
What’s driving it:
Structural stagnation at home is forcing outward expansion
A growing appetite for U.S. and European biotech assets, particularly in oncology and CNS
Policy pressure, including Tokyo’s push to improve capital efficiency and valuations
Flagship moves (e.g., Otsuka–Jnana ~$1B, Astellas–Iveric Bio $5.9B) validating cross-border M&A
The shift is cultural as much as financial. Japanese pharmas, historically conservative, are now adopting a U.S.-style external innovation model. (More)
"Innovation distinguishes between a leader and a follower"
Steve Jobs